You are here: Industry Insights > Johnson & Johnson

News List

Expert witness: Johnson & Johnson's role in opioid crisis may be 'worse' than Purdue's firstwordpharma
June 12, 2019
An expert testified in an ongoing Oklahoma lawsuit against Johnson & Johnson suggested that the company may have had an even greater role in the opioid crisis than Purdue Pharma, CNN reported Tuesday.
Johnson & Johnson's Balversa becomes first targeted therapy for metastatic bladder cancer in US firstwordpharma
April 14, 2019
Johnson & Johnson said Friday that it received accelerated approval by the FDA regarding its marketing application for ……
Holobiome and J&J collaborate for second time for microbiome therapeutics pharmatimes
April 04, 2019
Holobiome has announced a research collaboration with Johnson & Johnson Innovation, focusing on the creation of novel microbiome therapeutics.
Janssen laying off 4 dozen employees as California plant heads toward closure fiercepharma
April 03, 2019
Janssen is now focused in other areas and has decided the plant is no longer needed.
Holobiome Announces Second Collaboration with Johnson & Johnson Innovation to Create Novel Microbiome Therapeutics firstwordpharma
April 02, 2019
Holobiome, a biotechnology company developing microbiome therapeutics that target the gut-brain-axis……
Bayer, Johnson & Johnson to pay $775 million to settle US litigation related to Xarelto firstwordpharma
March 26, 2019
Bayer announced Monday that along with partner Johnson & Johnson, the companies have reached a deal in principle to pay $775 million to ……
Johnson & Johnson chalks up another talc loss with $29M mesothelioma verdict fiercepharma
March 15, 2019
As much as Johnson & Johnson would prefer it were otherwise, it's still mired in highly publicized talc litigation—and it's still having trouble persuading juries to decide in its favor.
Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression firstwordpharma
March 06, 2019
The FDA announced the approval of Johnson & Johnson's Spravato (esketamine), in conjunction with an oral antidepressant, for adults with treatment-resistant depression, with the nasal spray only available under a Risk Evaluation and Mitigation Strategy (R
Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression firstwordpharma
March 06, 2019
The FDA announced the approval of Johnson & Johnson's Spravato (esketamine), in conjunction with an oral antidepressant, for adults with treatment-resistant depression.
Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod fiercepharma
March 03, 2019
Johnson & Johnson’s Tremfya put a key rival on defense late last year with head-to-head data, and it’s keeping the heat on its competitors.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page